牛牛AI助理已提取核心訊息
EyePoint Pharmaceuticals officer David S. Jones is set to sell 10,104 shares of common stock on 02/02/2024, as per the latest filing. These shares, valued at an aggregate market value of $288,065.04, were acquired on the same day through the exercise of stock options, with the transaction involving a cash payment to the issuer. This sale follows a series of transactions over the past three months where a total of 72,983 shares were sold, amounting to gross proceeds of $1,753,183.17.
EyePoint Pharmaceuticals officer David S. Jones is set to sell 10,104 shares of common stock on 02/02/2024, as per the latest filing. These shares, valued at an aggregate market value of $288,065.04, were acquired on the same day through the exercise of stock options, with the transaction involving a cash payment to the issuer. This sale follows a series of transactions over the past three months where a total of 72,983 shares were sold, amounting to gross proceeds of $1,753,183.17.
根據最新文件，EyePoint製藥公司高管戴維·瓊斯定於2024年2月2日出售10,104股普通股。這些股票的總市值爲288,065.04美元，於當天通過行使股票期權收購，交易涉及向發行人支付現金。此次出售是在過去三個月進行的一系列交易之後進行的，共出售了72,983股股票，總收益爲1,753,183.17美元。
根據最新文件，EyePoint製藥公司高管戴維·瓊斯定於2024年2月2日出售10,104股普通股。這些股票的總市值爲288,065.04美元，於當天通過行使股票期權收購，交易涉及向發行人支付現金。此次出售是在過去三個月進行的一系列交易之後進行的，共出售了72,983股股票，總收益爲1,753,183.17美元。
有用
沒用